The inclusion of germline genetic testing for variants in genes such as BRCA1/2, ATM and CHEK2 are likely to be incorporated into mainstream testing for men presenting with locally advanced or metastatic disease. This evidence concerns the gene CHEK2 and metastatic neoplasm.